Table 1 Participants' characteristics (ATP immunogenicity cohort)
PHiD-CV group (N = 217) | Control group (N = 112) | Total (N = 329) | |
|---|---|---|---|
Gender (%), female/male | 50.2/49.8 | 50.9/49.1 | 50.5/49.5 |
Dose 1: | |||
mean age ± SD (weeks) | 7.1 ± 1.14 | 7.0 ± 1.16 | 7.1 ± 1.14 |
mean weight ± SD (kg) | 4.85 ± 0.76 | 4.74 ± 0.81 | 4.81 ± 0.78 |
mean weight-for-age Z-score ± SD | -0.45 ± 1.10 | -0.61 ± 1.17 | -0.50 ± 1.13 |
Dose 2: | |||
mean age ± SD (weeks) | 12.2 ± 1.28 | 12.1 ± 1.33 | 12.1 ± 1.30 |
mean weight ± SD (kg) | 5.80 ± 0.87 | 5.72 ± 0.93 | 5.78 ± 0.89 |
mean weight-for-age Z-score ± SD | -0.39 ± 1.14 | -0.49 ± 1.22 | -0.43 ± 1.17 |
Dose 3: | |||
mean age ± SD (weeks) | 17.1 ± 1.25 | 17.0 ± 1.32 | 17.1 ± 1.27 |
mean weight ± SD (kg) | 6.53 ± 0.90 | 6.39 ± 0.95 | 6.48 ± 0.92 |
mean weight-for-age Z-score ± SD | -0.31 ± 1.08 | -0.50 ± 1.17 | -0.37 ± 1.11 |
Mean interval between dose 3 and blood sampling visit (days) | 33.4 | 33.3 | 33.4 |